162 related articles for article (PubMed ID: 20921947)
1. β-Adrenoceptor blockade in sclerosing cholangitis of Mdr2 knockout mice: antifibrotic effects in a model of nonsinusoidal fibrosis.
Strack I; Schulte S; Varnholt H; Schievenbusch S; Töx U; Wendland K; Steffen HM; Drebber U; Dienes HP; Odenthal M
Lab Invest; 2011 Feb; 91(2):252-61. PubMed ID: 20921947
[TBL] [Abstract][Full Text] [Related]
2. Telmisartan plus propranolol improves liver fibrosis and bile duct proliferation in the PSC-like Abcb4-/- mouse model.
Mende S; Schulte S; Strack I; Hunt H; Odenthal M; Pryymachuck G; Quasdorff M; Demir M; Nierhoff D; Dienes HP; Goeser T; Steffen HM; Töx U
Dig Dis Sci; 2013 May; 58(5):1271-81. PubMed ID: 23247798
[TBL] [Abstract][Full Text] [Related]
3. Interferon-γ-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice.
Ravichandran G; Neumann K; Berkhout LK; Weidemann S; Langeneckert AE; Schwinge D; Poch T; Huber S; Schiller B; Hess LU; Ziegler AE; Oldhafer KJ; Barikbin R; Schramm C; Altfeld M; Tiegs G
J Hepatol; 2019 Oct; 71(4):773-782. PubMed ID: 31173810
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of p16 Decreases Biliary Damage and Liver Fibrosis in the Mdr2
Kyritsi K; Francis H; Zhou T; Ceci L; Wu N; Yang Z; Meng F; Chen L; Baiocchi L; Kundu D; Kennedy L; Liangpunsakul S; Wu C; Glaser S; Alpini G
Gene Expr; 2020 Nov; 20(2):89-103. PubMed ID: 32393417
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of microRNA-24 increases liver fibrosis by enhanced menin expression in Mdr2
Hall C; Ehrlich L; Meng F; Invernizzi P; Bernuzzi F; Lairmore TC; Alpini G; Glaser S
J Surg Res; 2017 Sep; 217():160-169. PubMed ID: 28602220
[TBL] [Abstract][Full Text] [Related]
6. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P; Fuchsbichler A; Wagner M; Zollner G; Kaser A; Tilg H; Krause R; Lammert F; Langner C; Zatloukal K; Marschall HU; Denk H; Trauner M
Gastroenterology; 2004 Jul; 127(1):261-74. PubMed ID: 15236191
[TBL] [Abstract][Full Text] [Related]
7. Knockout of the Tachykinin Receptor 1 in the Mdr2
Ceci L; Francis H; Zhou T; Giang T; Yang Z; Meng F; Wu N; Kennedy L; Kyritsi K; Meadows V; Wu C; Liangpunsakul S; Franchitto A; Sybenga A; Ekser B; Mancinelli R; Onori P; Gaudio E; Glaser S; Alpini G
Am J Pathol; 2020 Nov; 190(11):2251-2266. PubMed ID: 32712019
[TBL] [Abstract][Full Text] [Related]
8. TGF-β2 silencing to target biliary-derived liver diseases.
Dropmann A; Dooley S; Dewidar B; Hammad S; Dediulia T; Werle J; Hartwig V; Ghafoory S; Woelfl S; Korhonen H; Janicot M; Wosikowski K; Itzel T; Teufel A; Schuppan D; Stojanovic A; Cerwenka A; Nittka S; Piiper A; Gaiser T; Beraza N; Milkiewicz M; Milkiewicz P; Brain JG; Jones DEJ; Weiss TS; Zanger UM; Ebert M; Meindl-Beinker NM
Gut; 2020 Sep; 69(9):1677-1690. PubMed ID: 31992593
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2
Zhou T; Kyritsi K; Wu N; Francis H; Yang Z; Chen L; O'Brien A; Kennedy L; Ceci L; Meadows V; Kusumanchi P; Wu C; Baiocchi L; Skill NJ; Saxena R; Sybenga A; Xie L; Liangpunsakul S; Meng F; Alpini G; Glaser S
EBioMedicine; 2019 Oct; 48():130-142. PubMed ID: 31522982
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression.
Patsenker E; Popov Y; Stickel F; Jonczyk A; Goodman SL; Schuppan D
Gastroenterology; 2008 Aug; 135(2):660-70. PubMed ID: 18538673
[TBL] [Abstract][Full Text] [Related]
11. Activated hepatic stellate cells and portal fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice.
Nishio T; Hu R; Koyama Y; Liang S; Rosenthal SB; Yamamoto G; Karin D; Baglieri J; Ma HY; Xu J; Liu X; Dhar D; Iwaisako K; Taura K; Brenner DA; Kisseleva T
J Hepatol; 2019 Sep; 71(3):573-585. PubMed ID: 31071368
[TBL] [Abstract][Full Text] [Related]
12. Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic γδ T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease.
Tedesco D; Thapa M; Chin CY; Ge Y; Gong M; Li J; Gumber S; Speck P; Elrod EJ; Burd EM; Kitchens WH; Magliocca JF; Adams AB; Weiss DS; Mohamadzadeh M; Grakoui A
Gastroenterology; 2018 Jun; 154(8):2178-2193. PubMed ID: 29454797
[TBL] [Abstract][Full Text] [Related]
13. Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2
Fuchs CD; Dixon ED; Hendrikx T; Mlitz V; Wahlström A; Ståhlman M; Scharnagl H; Stojakovic T; Binder CJ; Marschall HU; Trauner M
Hepatol Commun; 2022 Sep; 6(9):2368-2378. PubMed ID: 35691019
[TBL] [Abstract][Full Text] [Related]
14. Genetic or pharmacological reduction of cholangiocyte senescence improves inflammation and fibrosis in the
Alsuraih M; O'Hara SP; Woodrum JE; Pirius NE; LaRusso NF
JHEP Rep; 2021 Jun; 3(3):100250. PubMed ID: 33870156
[TBL] [Abstract][Full Text] [Related]
15. Knockout of secretin receptor reduces biliary damage and liver fibrosis in Mdr2
Zhou T; Wu N; Meng F; Venter J; Giang TK; Francis H; Kyritsi K; Wu C; Franchitto A; Alvaro D; Marzioni M; Onori P; Mancinelli R; Gaudio E; Glaser S; Alpini G
Lab Invest; 2018 Nov; 98(11):1449-1464. PubMed ID: 29977037
[TBL] [Abstract][Full Text] [Related]
16. Bile acids modulate colonic MAdCAM-1 expression in a murine model of combined cholestasis and colitis.
Gao RY; Shearn CT; Orlicky DJ; Battista KD; Alexeev EE; Cartwright IM; Lanis JM; Kostelecky RE; Ju C; Colgan SP; Fennimore BP
Mucosal Immunol; 2021 Mar; 14(2):479-490. PubMed ID: 33004979
[TBL] [Abstract][Full Text] [Related]
17. Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis.
Liao L; Schneider KM; Galvez EJC; Frissen M; Marschall HU; Su H; Hatting M; Wahlström A; Haybaeck J; Puchas P; Mohs A; Peng J; Bergheim I; Nier A; Hennings J; Reißing J; Zimmermann HW; Longerich T; Strowig T; Liedtke C; Cubero FJ; Trautwein C
Gut; 2019 Aug; 68(8):1477-1492. PubMed ID: 30872395
[TBL] [Abstract][Full Text] [Related]
18. Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation.
Baghdasaryan A; Claudel T; Kosters A; Gumhold J; Silbert D; Thüringer A; Leski K; Fickert P; Karpen SJ; Trauner M
Gut; 2010 Apr; 59(4):521-30. PubMed ID: 20332524
[TBL] [Abstract][Full Text] [Related]
19. Modulation of the Tryptophan Hydroxylase 1/Monoamine Oxidase-A/5-Hydroxytryptamine/5-Hydroxytryptamine Receptor 2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis.
Kyritsi K; Chen L; O'Brien A; Francis H; Hein TW; Venter J; Wu N; Ceci L; Zhou T; Zawieja D; Gashev AA; Meng F; Invernizzi P; Fabris L; Wu C; Skill NJ; Saxena R; Liangpunsakul S; Alpini G; Glaser SS
Hepatology; 2020 Mar; 71(3):990-1008. PubMed ID: 31344280
[TBL] [Abstract][Full Text] [Related]
20. Endothelin Receptor-A Inhibition Decreases Ductular Reaction, Liver Fibrosis, and Angiogenesis in a Model of Cholangitis.
Owen T; Carpino G; Chen L; Kundu D; Wills P; Ekser B; Onori P; Gaudio E; Alpini G; Francis H; Kennedy L
Cell Mol Gastroenterol Hepatol; 2023; 16(4):513-540. PubMed ID: 37336290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
